NCT06311474 2026-03-18
RAINBOW
University of California, Los Angeles
Phase NA Completed
Clinical Trials
34 trialsNCT05626634 2025-12-03
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
Phase 2 Completed
NCT06975605 2025-11-18
Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.
GRIN Therapeutics, Inc.
Phase 1 Completed
NCT05323734 2025-07-11
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
Marinus Pharmaceuticals
Phase 3 Completed
NCT05059327 2025-06-04
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
Noema Pharma AG
Phase 2 Completed
NCT05495425 2024-11-22
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
Nobelpharma
Phase 3 Completed
NCT05286632 2024-11-06
KidneYou - Innovative Digital Therapy
Advice Pharma Group srl
Phase NA Completed
NCT04698538 2024-10-30
TRAIN
University of California, Los Angeles
Phase NA Completed
NCT02849457 2024-08-19
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
University of Alabama at Birmingham
Phase 2 Completed
NCT04595513 2024-05-16
STOP2
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT01906866 2024-04-23
Efficacy and Safety of CircadinĀ® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
Neurim Pharmaceuticals Ltd.
Phase 3 Completed
NCT03826628 2023-09-08
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
Dermatology Specialties Limited Partnership
Phase 2/3 Completed
NCT04285346 2023-04-04
TSC
Marinus Pharmaceuticals
Phase 2 Completed
NCT02544750 2022-07-14
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Jazz Pharmaceuticals
Phase 3 Completed
NCT03525834 2021-09-09
Safety and Efficacy of Everolimus (AfinitorĀ®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Novartis
Phase 4 Completed
NCT02451696 2021-09-01
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
NYU Langone Health
Phase 2 Completed
NCT01929642 2021-03-29
RAPT
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2 Completed
NCT03650452 2021-02-18
ELEKTRA
Takeda
Phase 2 Completed
NCT01526356 2020-10-26
Treatment
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT02201212 2020-09-16
Everolimus for Cancer With TSC1 or TSC2 Mutation
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02061397 2020-08-25
SOS
University of Pennsylvania
Phase 1/2 Completed
NCT02634931 2019-02-20
Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex
Nobelpharma
Phase 3 Completed
NCT02687633 2018-05-02
Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex
University of California, Los Angeles
Phase NA Completed
NCT01289912 2018-01-25
TSC
Boston Children's Hospital
Phase 2 Completed
NCT02104011 2018-01-23
STBETA
University Hospital, Bordeaux
Phase 2 Completed
NCT03140449 2017-05-04
Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis
National Taiwan University Hospital
Phase 3 Completed
NCT01070316 2017-03-13
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT02635789 2017-02-02
Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)
Nobelpharma
Phase 3 Completed
NCT00789828 2016-02-03
EXIST-1
Novartis
Phase 3 Completed
NCT00989742 2015-12-02
Doxycycline In Lymphangioleiomyomatosis (LAM)
University of Nottingham
Phase 4 Completed
NCT01903681 2014-04-04
Assessment of the Pharmacokinetics of CircadinĀ® in Children With Neurodevelopmental Disorders and Sleep Disturbances
Neurim Pharmaceuticals Ltd.
Phase 1 Completed
NCT00792766 2013-09-18
Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT01031901 2012-02-27
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
The University of Texas Health Science Center, Houston
Phase 1 Completed
NCT00457808 2007-04-09
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
Children's Hospital Medical Center, Cincinnati
Phase 2 Completed